financetom
Business
financetom
/
Business
/
Kits Eyecare Swings to Q4 Profit on Revenue Jump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kits Eyecare Swings to Q4 Profit on Revenue Jump
Mar 5, 2025 4:23 AM

07:14 AM EST, 03/05/2025 (MT Newswires) -- Kits Eyecare ( KTYCF ) on Wednesday reported a fourth-quarter swing to profit as revenue jumped 42%.

The online eyewear retailer said net income was $2.7 million or $0.08 per share, compared with a net loss of $0.5 million, or $0.02 per share, in the prior year period.

Revenue surged 42% to $44.8 million, helped by greater recognition of the Kits brand and strong customer demand, operational efficiencies, and strategic initiatives. The company said glasses revenue increased by 60% to a record $6.5 million in the quarter.

Kits is guiding to first-quarter revenue of $46 million to $48 million.

"2024 was another record-setting year for KITS as we continued to build momentum and strengthen our leadership in the eyewear category," said chief executive Roger Hardy. "The fourth quarter was a standout, with multiple record-breaking sales weeks and a major milestone of our first 1 million pairs of glasses delivered."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Sep 24, 2025
Sept 24 (Reuters) - Miner Freeport-McMoRan said on Wednesday that it was expecting consolidated sales to be about 4% lower for copper and nearly 6% lower for gold in the third quarter, compared with its prior forecast. (Reporting by Pooja Menon in Bengaluru; Editing by Anil D'Silva) ...
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Sep 24, 2025
08:11 AM EDT, 09/24/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday that Australia's Therapeutic Goods Administration approved Leqembi for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease. The approval follows a review process after the regulatory agency initially did not approve the drug in February, the company said. Leqembi targets toxic protofibrils and...
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Sep 24, 2025
Sept 24 (Reuters) - Harmony Biosciences ( HRMY ) said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial. ...
Two US senators urge Tinder parent to act against dating scams on its apps
Two US senators urge Tinder parent to act against dating scams on its apps
Sep 24, 2025
(Reuters) -Two U.S. senators sent a letter to Tinder parent Match on Wednesday, pushing for action against dating scams on the company's platforms and asking for information about its efforts to detect frauds and protect its users. In a letter to Match CEO Spencer Rascoff, Democratic Senator Maggie Hassan and Republican Senator Marsha Blackburn asked the company to provide documents...
Copyright 2023-2026 - www.financetom.com All Rights Reserved